Intellia Therapeutics, Inc.
NTLA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,902,947 | $973,006 | $735,885 | $1,187,629 |
| - Cash | $193,389 | $156,172 | $126,880 | $189,182 |
| + Debt | $97,966 | $102,591 | $119,253 | $210,198 |
| Enterprise Value | $1,807,524 | $919,425 | $728,258 | $1,208,645 |
| Revenue | $13,782 | $14,245 | $16,627 | $12,874 |
| % Growth | -3.3% | -14.3% | 29.2% | – |
| Gross Profit | -$65,167 | $14,245 | $16,627 | $12,874 |
| % Margin | -472.8% | 100% | 100% | 100% |
| EBITDA | -$96,388 | -$107,522 | -$118,309 | -$133,881 |
| % Margin | -699.4% | -754.8% | -711.5% | -1,039.9% |
| Net Income | -$101,324 | -$101,255 | -$114,329 | -$128,898 |
| % Margin | -735.2% | -710.8% | -687.6% | -1,001.2% |
| EPS Diluted | -0.92 | -0.98 | -1.1 | -1.27 |
| % Growth | 6.1% | 10.9% | 13.4% | – |
| Operating Cash Flow | -$76,899 | -$99,622 | -$148,930 | -$85,195 |
| Capital Expenditures | -$29 | -$239 | -$735 | -$981 |
| Free Cash Flow | -$76,928 | -$99,861 | -$149,665 | -$86,176 |